Randall Quinn, MD
Family Medicine · Cullman, ALNPI 1801817523
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 456 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 456 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Astellas Pharma US Inc$848
- Novo Nordisk$660
- AstraZeneca$599
- GSK$592
- E.r. Squibb & Sons, L.L.C.$373
- plus $3K from 31 others
Across 315 payments — averaging $17,190 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$1.4M
- Seqirus USA Inc$866K
- AstraZeneca$628K
- Astrazeneca UK Limited$556K
- Roche Molecular Systems, Inc.$441K
- Eli Lilly$328K
- plus $1.2M from 12 others
What the payments were for
- Food & beverage$7,50497%
- Education$2003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 106 | $1,645 |
| Astellas Pharma US Inc | 43 | $848 |
| Novo Nordisk | 35 | $660 |
| AstraZeneca | 35 | $599 |
| GSK | 37 | $592 |
| E.r. Squibb & Sons, L.L.C. | 23 | $373 |
| Johnson & Johnson | 25 | $361 |
| Amgen | 19 | $314 |
| Boehringer Ingelheim | 16 | $227 |
| Exact Sciences | 12 | $223 |
| Novartis | 13 | $221 |
| AbbVie(2 entities) | 12 | $212 |
| Lilly USA, LLC | 11 | $196 |
| Merck | 11 | $168 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $140 |
| Bayer | 6 | $121 |
| Dexcom, Inc. | 6 | $108 |
| Lundbeck LLC | 5 | $85 |
| Amarin Pharma, Inc. | 5 | $81 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Eisai Inc. | 3 | $55 |
| Sumitomo Pharma America, Inc. | 3 | $48 |
| Shield Therapeutics Inc | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Sanofi | 1 | $28 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Biogen | 1 | $22 |
| Endogastric Solutions, Inc | 1 | $18 |
| Abbott | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$7,704 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 204 | $199,562 |
| JardianceEmpagliflozin | 96 | $84,282 |
| MyrbetriqMirabegron | 79 | $51,062 |
| FarxigaDapagliflozin Propanediol | 57 | $45,255 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $40,161 |
| JanuviaSitagliptin Phosphate | 44 | $34,806 |
| OzempicSemaglutide | 30 | $27,012 |
| EntrestoSacubitril/Valsartan | 24 | $20,872 |
| XareltoRivaroxaban | 17 | $20,309 |
| TradjentaLinagliptin | 22 | $19,162 |
| MounjaroTirzepatide | 15 | $17,530 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 546 | $14,012 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $11,630 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $11,438 |
| BrilintaTicagrelor | 19 | $10,997 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,645 | $199,562204 claims |
| Boehringer IngelheimJardiance, Tradjenta | $227 | $103,444118 claims |
| AstraZenecaFarxiga, Brilinta | $599 | $56,25176 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $592 | $51,60084 claims |
| Astellas Pharma US IncMyrbetriq | $848 | $51,06279 claims |
| MerckJanuvia | $168 | $34,80644 claims |
| Novo NordiskOzempic | $660 | $27,01230 claims |
| NovartisEntresto | $221 | $20,87224 claims |
| Johnson & JohnsonXarelto | $361 | $20,30917 claims |
| Lilly USA, LLCMounjaro | $196 | $17,53015 claims |
| AbbVieLinzess | $212 | $5,73611 claims |
| Sanofi-aventis U.S. LLCLantus | $36 | $2,70916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Cullman
- Lashelle BarmoreBirmingham$486K
- Regina BenjaminBayou la Batre$222K
- Jonathan ParkerMuscle Shoals$214K
- Kathleen DupperHuntsville$210K
- Whitney TewHuntsville$114K
- Kelly HunterTuscaloosa$84K
- Daniel EnglertHuntsville$82K
- Joel LaughlinMobile$75K
- Ashleigh Butts-WilkersonMobile$54K
- Philip WilsonDothan$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.